Skip to content

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
PreclinicalGrowth HormoneSubQ1–3x per day

CJC-1295 + Ipamorelin

CJC/Ipa · GHRH + GHRP combo

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

§ 01   Overview

Overview

Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone.

Widely used in research / compounding; no late-stage FDA outcome trials.

§ 02   Mechanism

Mechanism of action

Combines the short-acting GHRH analog CJC-1295 (no DAC) with the selective ghrelin receptor agonist Ipamorelin. The two act on different pituitary receptors and produce a larger GH pulse than either alone.

  • 01Larger physiological GH pulses
  • 02Improved recovery and sleep anecdotally
  • 03Clean side-effect profile of Ipamorelin preserved

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
5 mg / 5 mg combo vial
BAC Water
2 ml BAC water
Dose Range
100 – 300 mcg of each peptide
Starting Dose
100 mcg CJC + 100 mcg Ipamorelin
Route
SubQ
Timing
Before bed or pre-workout, empty stomach
Frequency
1–3x per day
Cycle
8–12 weeks on, 4 off

§ 04   Evidence

Evidence & research

Preclinical

Widely used in research / compounding; no late-stage FDA outcome trials.

FDA Status

Not FDA-approved.

§ 05   Stacks

Common stacks

§ 06   News

In the news

6 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

Telehealth (Rx) · 3

Telehealth

Defy Medical

Rx required

Broadest peptide formulary in legitimate US telehealth. 13-year history, concierge cash-pay, no known lawsuits.

Visit
Telehealth

Marek Health

Rx required

Premium hormone optimization. All 50 states. 4.8 Trustpilot. Partners include Hallandale.

Visit
Telehealth

Blokes / Joi Women's Wellness

Rx required

Men's + women's optimization platform. TRT in 34 states. 4.6–4.8 Trustpilot.

Visit

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Flushing, mild water retention

Contraindications

None specified.

§ 10   Questions

CJC-1295 + Ipamorelin FAQ

What is CJC-1295 + Ipamorelin?
Classic GHRH + GHRP combination that amplifies endogenous GH pulses more than either alone. Combines the short-acting GHRH analog CJC-1295 (no DAC) with the selective ghrelin receptor agonist Ipamorelin. The two act on different pituitary receptors and produce a larger GH pulse than either alone.
What is CJC-1295 + Ipamorelin used for?
Reported uses include larger physiological gh pulses, improved recovery and sleep anecdotally, and clean side-effect profile of ipamorelin preserved. Evidence strength is rated Preclinical — see the evidence section for detail.
How is CJC-1295 + Ipamorelin dosed?
Commonly referenced dosing is 100 – 300 mcg of each peptide, typically 1–3x per day, administered SubQ. This is educational reference only; consult a licensed clinician before use.
How do you reconstitute CJC-1295 + Ipamorelin?
For CJC-1295 + Ipamorelin, vials commonly come in 5 mg / 5 mg combo vial and a common reconstitution is 2 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
What are the side effects of CJC-1295 + Ipamorelin?
Commonly reported side effects include flushing, mild water retention. This list is not exhaustive.
Is CJC-1295 + Ipamorelin legal?
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.